13 In 1993, The Journal of Clinical Apheresis published a paper detailing the use of TPE as either a first- or second-line therapy to be used with other modalities on disorders such as Raynauds disease, systemic lupus erythematosus, coagulation factor inhibitors, familial hypercholesterolemia, acute Guillain-Barr syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, cryoglobulinemia, Goodpastures syndrome, and thrombotic thrombocytopenic purpura
Sensacin de enrojecimiento o mareo: Puede ocurrir durante una infusin intravenosa, pero generalmente se resuelve rpidamente
10.1016/j.pbb.2006.09.008 Pharmacol Biochem Behav
20 mg*** Other Ingredients: Taploca syrup, cane sugar, palm oil, natural flavors, sunflower lecithin, citric acid, fruit and vegetable juice (color), and sea salt
Treatment frequency depends on your individual needs and should be discussed during your consultation